GoodRx has placed 34 615 384 shares of common stock in an IPO at a price of $33 per share, which is $5 above the upper limit of the initially announced range ($28-33). Besides, GoodRx has granted the underwriters a 30-day option to purchase up to 5 192 307 shares of common stock at a price of public offering.
The trading debut will take place on September 23 on the Nasdaq Global Select Market under the ticker symbol “GDRX”.